NCT03393026View on ClinicalTrials.gov

A Study of Lurasidone HCl in Subjects With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

September 17, 2019

Study Completion Date

September 17, 2019

Conditions
Schizophrenia
Interventions
DRUG

Lurasidone

Lurasidone 40-160 mg/day for 6 weeks

Trial Locations (2)

Unknown

Taipei City Hospital, Songde Branch, Taipei

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

Standard Chem. & Pharm. Co., Ltd.

INDUSTRY

NCT03393026 - A Study of Lurasidone HCl in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter